Early age of onset predicts severity of visual impairment in patients with neuromyelitis optica spectrum disorder.

Mult Scler

Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.

Published: October 2021

AI Article Synopsis

  • The study focuses on severe residual visual loss (SRVL) in patients with neuromyelitis optica spectrum disorders (NMOSD) and aims to identify predictors of this condition.
  • Researchers analyzed data from 106 patients, finding that those who experienced SRVL typically had an earlier age of disease onset compared to those who did not.
  • The findings suggest that patients younger than 21 at disease onset have a significantly higher risk for SRVL and may benefit from more effective treatments upfront.

Article Abstract

Background: Severe residual visual loss (SRVL) is frequent in neuromyelitis optica spectrum disorders (NMOSD). Identifying higher-risk patients at onset is important to prevent disability accumulation.

Objective: To determine predictors of SRVL in a large NMOSD cohort.

Methods: Patient characteristics at last visual acuity (VA) evaluation were retrospectively collected. VA was scored 0: better than 20/40, 1: 20/40-20/99, 2: 20/100-20/200, and 3: worse than 20/200. SRVL was defined as a combined score (VA worst + best eye) ⩾ 4. Descriptive statistics were used to compare groups and logistic regression to evaluate predictors of VA.

Results: 106 patients (mean age at disease onset (AO): 35.8 ± 16.5 years) were included. Patients with SRVL had earlier AO (mean: 26.7 vs 38.0 years) compared to non-SRVL group ( = 0.005). Patients with AO < 21 years were more likely to have SRVL, be blind, present with binocular optic neuritis, have recurrent optic neuritis, and receive oral therapy first-line than those with AO ⩾ 21. After adjusting for race, sex, and disease duration, the odds of SRVL were 4.68 times higher in patients < 21 at disease onset (95% CI: 1.53-14.34, = 0.007).

Conclusion: Early AO predicts SRVL in NMOSD, independent of disease duration. High-efficacy therapies should be considered for first-line treatment in this group.

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458520981736DOI Listing

Publication Analysis

Top Keywords

neuromyelitis optica
8
optica spectrum
8
disease onset
8
optic neuritis
8
disease duration
8
srvl
7
patients
6
early age
4
onset
4
age onset
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!